A complement Factor B test examines a protein that is indispensable to the alternative complement pathway—the immune system’s continuously available amplification circuit. The result can help investigate recurrent invasive infections, unexplained low C3, suspected complement-mediated kidney disease, or an abnormal alternative-pathway functional screen. However, “Factor B testing” may refer to several different measurements. An antigen assay measures how much intact Factor B is present; a functional assay asks whether the pathway works; and a Bb or CBb assay measures a cleavage product created during activation. Those results cannot be interpreted as though they were interchangeable. Low intact Factor B may reflect inherited deficiency, active consumption, reduced production, or protein loss. A normal concentration does not exclude a dysfunctional protein or a gain-of-function variant. The most useful interpretation combines the test type with C3, C4, AH50, CH50, kidney findings, infection history, medications, and specimen quality.
- Factor B is required to build the alternative-pathway C3 and C5 convertases.
- An antigen result measures quantity, not necessarily biological performance.
- A low AH50 with a normal CH50 localizes a defect toward the alternative pathway.
- Elevated Bb or CBb suggests activation; it does not mean excess intact Factor B.
- Low Factor B can result from deficiency, consumption, protein loss, or treatment.
- Normal Factor B does not rule out complement dysregulation or a pathogenic CFB variant.
Table of Contents
- Why Factor B has an outsized role in complement
- Which Factor B test was actually performed?
- What a low Factor B result can mean
- Activation, kidney disease, and CFB variants
- How to read Factor B with AH50, CH50, C3, and C4
- Preanalytic, medication, and timing effects
- What clinicians usually do next
Why Factor B has an outsized role in complement
Factor B is a circulating serine-protease precursor made mainly by the liver, with additional local production by immune and tissue cells. It belongs specifically to the alternative complement pathway. Unlike the classical pathway, which is commonly initiated by antibodies bound to a target, the alternative pathway maintains low-level background activity and rapidly amplifies complement deposited by any of the three initiating pathways.
The sequence begins when Factor B binds C3b, or a water-hydrolyzed form of C3. Factor D then cleaves bound Factor B into Ba and Bb. Ba separates, while Bb remains attached to C3b. The resulting complex, C3bBb, is the alternative-pathway C3 convertase. It cleaves more C3, generating more C3b and creating a positive-feedback loop. Adding another C3b changes the complex into a C5 convertase, which starts terminal-pathway assembly and membrane attack complex formation.
This position makes Factor B both a gatekeeper and an accelerator. Without usable Factor B, the alternative pathway cannot construct its characteristic convertase. With overactive or poorly regulated Factor B, the same amplification loop can consume C3 and injure host tissue. Factor H, Factor I, membrane cofactor protein, decay-accelerating factor, and other regulators normally restrain the loop. Properdin stabilizes the convertase on selected surfaces.
The clinical consequence depends on which direction the system fails. Complete loss of Factor B function weakens defense against bacteria, particularly when antibody and other complement mechanisms cannot compensate. Excessive or persistent activity is associated with disorders such as C3 glomerulopathy and complement-mediated thrombotic microangiopathy. A test therefore is not merely asking whether a number is “high” or “low.” It is trying to place Factor B within a dynamic system of activation, amplification, regulation, and consumption.
This is why an isolated Factor B value rarely supplies a diagnosis. A patient with recurrent meningococcal infection and an absent AH50 alternative-pathway result poses a different question from a patient with hematuria, proteinuria, low C3, and elevated activation fragments. The same analyte can participate in both immune deficiency and tissue-damaging overactivation.
Which Factor B test was actually performed?
The report name and methodology matter. Laboratories may offer Factor B as part of a specialized complement panel rather than as a routine stand-alone test. Four categories are especially important.
Factor B antigen or concentration measures the amount of immunoreactive Factor B in serum or plasma. A laboratory may report milligrams per deciliter with its own reference interval. This is principally a quantity test. A low value supports reduced circulating protein, but a value within range does not prove that the molecule binds C3b, undergoes normal cleavage, or forms a properly regulated convertase.
Alternative-pathway function, commonly reported as AH50 or an equivalent pathway-specific assay, measures the pathway’s combined ability to activate complement under alternative-pathway conditions. It depends not only on Factor B but also on Factor D, properdin, C3, and terminal components C5 through C9, among other factors. An abnormal result can raise suspicion for Factor B deficiency, but it cannot identify Factor B by itself. Component-specific testing or mixing/reconstitution studies may be required.
Bb or CBb activation fragments measure products generated when Factor B is cleaved. The naming varies with assay design. An elevated fragment can be evidence that alternative-pathway convertases have recently formed. This is conceptually different from an antigen measurement. During intense activation, intact Factor B may be consumed while Bb rises. Reading “Factor B low” and “Bb high” as contradictory misses the biology: one can describe depleted substrate while the other records its use.
Genetic testing examines CFB, the gene encoding Factor B. It may identify biallelic loss-of-function variants in a deficiency phenotype or heterozygous gain-of-function and other disease-associated variants in complement-mediated kidney or vascular disease. Genetics does not replace biochemical assessment. A variant of uncertain significance is not a diagnosis, and some pathogenic variants leave the antigen concentration normal.
Some advanced panels also include C3, C4, Factor H, soluble C5b-9, autoantibodies, and pathway function. The first interpretation step should therefore be to identify the exact specimen, method, units, and laboratory interval. Comparing a result with a range from another laboratory—or comparing antigen with activation-fragment cutoffs—can produce a false conclusion.
What a low Factor B result can mean
A low antigen concentration has several possible mechanisms. The clinical setting and companion tests determine which is plausible.
Inherited Factor B deficiency is extremely rare. Complete deficiency follows an autosomal recessive pattern and disables alternative-pathway function. Reported patients may experience severe or recurrent bacterial infections, including meningococcal and pneumococcal disease, although the phenotype can vary. The classical pathway remains capable of initiating complement, so infection susceptibility is not identical to complete C3 deficiency. A convincing diagnosis generally requires repeat low or absent Factor B, an abnormal pathway pattern, demonstration that adding Factor B restores activity when available, and molecular confirmation.
A partial reduction is more difficult to interpret. Heterozygous carriers may have lower concentrations without the severe phenotype of complete deficiency. A single modestly low result should not be converted directly into a hereditary diagnosis, especially during acute illness.
Consumption during complement activation can lower intact Factor B. In alternative-pathway dysregulation, convertase formation repeatedly cleaves Factor B into Ba and Bb. Low C3, elevated Bb/CBb, elevated soluble C5b-9, active kidney disease, or a changing result over time can support consumption. This is an acquired biochemical state, not necessarily a germline deficiency.
Reduced synthesis is possible in advanced liver dysfunction because the liver produces much of circulating Factor B. The result should be interpreted with albumin, coagulation tests, liver enzymes, and the broader clinical picture rather than assigned to complement deficiency in isolation.
Protein loss can reduce multiple plasma proteins. Nephrotic-range urinary loss, protein-losing enteropathy, extensive burns, or large-volume plasma losses can produce a secondary low concentration. Urinalysis, urine protein quantification, serum albumin, and other complement components help reveal the pattern.
Dilution or replacement therapy can change measured concentration. Massive transfusion, plasma infusion, therapeutic plasma exchange, or substantial intravenous fluid resuscitation may either dilute a patient’s proteins or introduce donor complement. The direction depends on timing and product. A sample drawn after plasma exchange may no longer represent the untreated state.
Complement-directed treatment also matters. A Factor B inhibitor is intended to suppress Factor B-dependent activity. Some agents reduce functional activity without lowering immunoreactive antigen, whereas synthesis-suppressing approaches could lower both protein and fragments. Results must be interpreted according to the drug’s target, dose, and sampling interval.
A low result merits attention when it is reproducible and fits the phenotype. Fever with rapidly progressive illness, neck stiffness, a non-blanching rash, confusion, or shock requires emergency evaluation regardless of whether a complement diagnosis is already established.
Activation, kidney disease, and CFB variants
Factor B testing is increasingly encountered in nephrology because the alternative pathway can damage glomeruli and vascular endothelium. Yet no Factor B blood result can substitute for defining the renal syndrome.
In C3 glomerulopathy, dysregulated alternative-pathway activity causes dominant C3 deposition in the kidney. Patients may have hematuria, proteinuria, hypertension, reduced kidney function, and low serum C3, but blood findings vary. Kidney biopsy is required to establish and classify the lesion; serum complement tests help investigate mechanism, prognosis, family implications, and potential targeted therapy. The Complement C3 test is especially informative because persistent alternative-pathway turnover often lowers C3 while C4 remains normal.
Complement-mediated thrombotic microangiopathy can present with thrombocytopenia, microangiopathic hemolytic anemia, and organ injury, commonly involving the kidneys. It is a clinical emergency with several competing causes. ADAMTS13 testing, Shiga-toxin evaluation when appropriate, medication and transplant history, blood pressure, pregnancy context, autoimmune testing, infection assessment, and other investigations may be more urgent than a Factor B result. Alternative-pathway panels are typically second-order studies, not a reason to delay treatment.
CFB variants can affect disease in different ways. Biallelic loss-of-function variants may cause deficiency. By contrast, certain gain-of-function variants increase convertase formation, stability, or resistance to regulation and are associated with complement-mediated kidney disease. A person with a gain-of-function variant may have a normal Factor B antigen concentration because the problem is behavior, not quantity. Some variants confer susceptibility rather than certainty: a trigger such as infection, pregnancy, transplantation, or severe inflammation may help precipitate disease, and penetrance can be incomplete.
Acquired drivers can mimic genetic dysregulation. C3 nephritic factors stabilize the C3 convertase; antibodies against Factor H or other pathway proteins can disturb regulation. Monoclonal immunoglobulins may also alter complement in some adults. Consequently, a comprehensive evaluation may include autoantibodies, paraprotein testing, genetic analysis, and functional assays rather than CFB sequencing alone.
Factor B has also become a therapeutic target. Inhibiting Factor B interrupts alternative-pathway C3 and C5 convertase activity while leaving the initiating classical and lectin pathways relatively intact. This selectivity can reduce tissue-damaging amplification but still changes infection defenses. A low AH50 during therapy may be an expected pharmacodynamic effect, not evidence that the patient has inherited Factor B deficiency.
How to read Factor B with AH50, CH50, C3, and C4
A pathway pattern is more informative than one analyte. The table below is a reasoning guide, not a substitute for the performing laboratory’s interpretation.
| Pattern | What it suggests | Important alternatives |
|---|---|---|
| Low or absent AH50, normal CH50 | Defect affecting an alternative-pathway-specific component, including Factor B, Factor D, or properdin | Factor H or Factor I abnormalities, pathway-targeted therapy, specimen problem |
| Low AH50 and low CH50 | Defect in shared components C3 or C5–C9, broad consumption, or complement blockade | Multiple deficiencies, severe systemic activation, mishandled sample |
| Normal AH50, low CH50 | Early classical-pathway defect involving C1, C2, or C4 | Classical-pathway consumption or assay interference |
| Low Factor B antigen, low C3, elevated Bb/CBb | Alternative-pathway consumption is plausible | Protein loss plus inflammation, treatment effects |
| Low Factor B antigen, low AH50, normal CH50, stable C3 | Factor B deficiency becomes more plausible | Factor D/properdin defect plus unrelated low antigen, laboratory error |
| Normal Factor B antigen, abnormal AH50 | Functional Factor B abnormality or another pathway component defect | Complement inhibitor, severe deficiency of Factor D/properdin, preanalytic degradation |
| Normal Factor B antigen, normal AH50, renal phenotype | Does not exclude episodic or surface-restricted dysregulation | CFB/CFH variants, nephritic factors, non-complement kidney disease |
The CH50 total complement test assesses the classical pathway through the shared terminal sequence. Pairing it with AH50 helps localize where function is failing. It does not determine whether the cause is inherited, acquired, pharmacologic, or preanalytic.
C3 and C4 add a consumption pattern. Alternative-pathway-predominant activation often produces low C3 with preserved C4. Low C3 and low C4 suggest broader classical-pathway activation, severe systemic consumption, or a mixed process. Normal values do not exclude localized disease, intermittent activation, or a function-altering variant.
Activation markers add another time dimension. Intact proteins are a supply measurement; fragments are evidence of recent use. Soluble C5b-9 reflects terminal-pathway activation downstream, but it is not specific for a disease. Trends obtained under comparable clinical and treatment conditions are generally more meaningful than unrelated single measurements.
A “high” Factor B antigen is usually less diagnostically specific than a low one. Factor B can behave as an acute-phase reactant, so inflammation may raise production. High concentration alone does not establish alternative-pathway overactivation, because activation requires cleavage and convertase assembly. Bb/CBb, C3 breakdown products, soluble C5b-9, and functional context are better suited to that question.
Age, pregnancy, laboratory platform, and population characteristics may also influence reference intervals. The correct comparison is the interval printed by the performing laboratory, not a value copied from a different hospital or online source. When serial monitoring is clinically important, using the same laboratory and method reduces apparent changes caused by assay differences rather than biology.
Preanalytic, medication, and timing effects
Complement is unusually sensitive to specimen handling because activation can continue after blood collection while functional proteins can degrade. Specialized laboratories commonly require prompt processing, separation, freezing, and frozen transport. The exact instructions differ for serum, EDTA plasma, antigen assays, activation fragments, and functional tests.
A warm or delayed sample may allow ex vivo activation, potentially changing intact components and fragments. Repeated freeze-thaw cycles can reduce function. Gross hemolysis or lipemia may cause rejection or interference depending on the method. A result that conflicts sharply with the clinical picture should be discussed with the laboratory before extensive conclusions are drawn.
Timing during acute inflammation is also important. Infection can activate complement and lower some components while increasing hepatic synthesis of acute-phase proteins. A sample collected during critical illness may identify clinically relevant consumption, but it may not reveal the patient’s baseline. Repeating testing after recovery can separate transient activation from a persistent inherited or regulatory abnormality.
Medication review should include complement inhibitors, immunoglobulin replacement, plasma products, immunosuppressants, and therapies used for kidney or hematologic disease. Factor B-targeted drugs predictably suppress alternative-pathway function. C3 and C5 inhibitors alter downstream assays differently. Anti-C5 treatment can make both AH50 and CH50 very low because C5 is shared, while Factor B inhibition is expected to affect AH50 more directly. The assay platform and drug concentration can influence the observed pattern.
Plasma infusion can temporarily supply Factor B to a deficient patient. Intravenous immunoglobulin does not simply replace Factor B, but it can affect immune-complex biology and some serologic evaluations. Therapeutic plasma exchange removes patient proteins and autoantibodies while adding replacement fluid, making post-procedure complement values difficult to attribute.
When complement-mediated thrombotic microangiopathy or severe glomerular disease is suspected, ideal pre-treatment samples are valuable, but urgent care must not be delayed solely to obtain them. The clinical team can collect and freeze specimens rapidly when feasible and document exactly when therapies began.
What clinicians usually do next
The next step depends on whether the concern is infection susceptibility, kidney injury, or a treatment effect.
For recurrent or unusually severe bacterial infection, clinicians generally confirm the history with organism records, sites of infection, age at first event, vaccination status, and family history. Paired AH50 and CH50 are first-line functional screens. If AH50 is repeatedly absent while CH50 is preserved, component-specific measurements may include Factor B, Factor D, and properdin. Functional restoration or mixing studies, when available, can identify which missing protein corrects the pathway. Genetic counseling and CFB testing can confirm inheritance and guide testing of relatives.
A confirmed complement deficiency prompts an individualized prevention plan. This may include age-appropriate meningococcal, pneumococcal, and Haemophilus influenzae type b vaccination; consideration of antimicrobial prophylaxis; and explicit instructions for urgent assessment of fever or meningococcal symptoms. Vaccination reduces risk but does not eliminate it. Household and family recommendations depend on the identified disorder and local public-health guidance.
For hematuria, proteinuria, hypertension, declining estimated glomerular filtration rate, or suspected thrombotic microangiopathy, the workup broadens. Common components include complete blood count, blood smear, lactate dehydrogenase, haptoglobin, creatinine, urinalysis, urine protein quantification, C3, C4, AH50, CH50, and disease-specific testing. Nephrology may recommend kidney biopsy. Specialized complement panels can assess Factor H, Bb/CBb, soluble C5b-9, nephritic factors, and autoantibodies. Genetics may include CFB and regulatory genes, but results must be interpreted by experts because uncertain variants are common.
The Complement C4 test helps determine whether activation is predominantly alternative-pathway or involves the classical pathway as well. A normal C4 does not prove C3 glomerulopathy, and a low C4 does not exclude complement-mediated kidney disease. The result is one piece of a clinicopathologic assessment.
For a patient already receiving a complement inhibitor, the clinical question should be explicit: is the test checking drug effect, breakthrough activity, adherence, or an underlying diagnosis? The expected laboratory pattern differs by target. Testing should use the same method and a consistent relationship to dosing when longitudinal comparison matters.
The central principle is to distinguish amount, activity, and activation. Factor B antigen asks how much recognizable protein is present. AH50 asks whether the alternative pathway can execute its task. Bb/CBb asks whether Factor B has recently been cleaved. Genetics asks why the system may behave abnormally. None should be made to answer a question it was not designed to answer.
References
- Atypical Hemolytic Uremic Syndrome Complement Panel, Serum and Plasma. Mayo Clinic Laboratories. Laboratory test information, updated 2026.
- Alternative Complement Pathway, Functional, Serum. Mayo Clinic Laboratories. Laboratory test information, updated 2026.
- Factor B as a therapeutic target for the treatment of complement-mediated diseases. Frontiers in Immunology. Review, 2025.
- Complement deficiencies and infections. Current Opinion in Immunology. Review, 2026.
- Complement deficiencies. Immune Deficiency Foundation. Clinical education resource, updated 2025.
- Rare Kidney Disease C3G: Types, Diagnosis, and New Therapies. National Kidney Foundation. Patient and clinician education resource, 2026.
Disclaimer
This article is for general educational purposes and does not diagnose complement deficiency, kidney disease, or any other condition. Laboratory methods and reference intervals vary, and results must be interpreted with symptoms, medications, specimen handling, and companion tests by a qualified clinician. Seek emergency care for rapidly progressive fever, severe headache, neck stiffness, confusion, a non-blanching rash, breathing difficulty, or signs of shock.
